Rockley Photonics, a global company involved in photonics-based health monitoring and communications solutions recently announced that it has named Richard Kuntz, MD, MSc to its board of directors, as an independent director effective August 8, 2022.
“We are delighted to welcome Richard Kuntz to our board of directors. A proven leader in healthcare, Rick brings a blend of world-class industry, clinical, and research experience that makes him uniquely qualified to serve on our board,” said Dr Andrew Rickman, chairman and chief executive officer of Rockley Photonics. “His broad background spans multiple aspects of healthcare, from leading Medtronic’s neuromodulation business and subsequently serving as Medtronic’s global chief medical and scientific officer to serving as an associate professor of medicine at Harvard Medical School. Having applied our board skills matrix to assess our existing competencies, we determined that Rick’s academic and industry experience will complement the competencies of our board.”
Before his 17-year experience at Medtronic, Dr Kuntz was the founder and CSO of the Harvard Clinical Research Institute, a university-based contract research organisation which coordinates National Institutes of Health (NIH) and industry clinical trials with the US Food and Drug Administration. Furthermore, he has also directed numerous multicentre clinical trials and authored more than 250 original peer-reviewed publications. He has also served as an associate professor of medicine at Harvard Medical School, chief of the division of clinical biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women’s Hospital in Boston. He also has served as a member of the board of governors of the Patient-Centred Outcomes Research Institute (PCORI), part of the Affordable Care Act, from 2010-2018.
He graduated from Miami University and received his medical degree from Case Western Reserve University School of Medicine, and completed his residency and chief residency in internal medicine at the University of Texas Southwestern Medical School, Parkland Hospital, Dallas and his fellowships in cardiovascular diseases and interventional cardiology at the Beth Israel Hospital and Harvard Medical School, Boston.
